These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 19096156)

  • 1. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.
    Wilcock DM; Colton CA
    J Alzheimers Dis; 2008 Dec; 15(4):555-69. PubMed ID: 19096156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
    Cribbs DH
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-beta immunotherapy for Alzheimer's disease.
    Fu HJ; Liu B; Frost JL; Lemere CA
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing novel immunogens for an effective, safe Alzheimer's disease vaccine.
    Maier M; Seabrook TJ; Lemere CA
    Neurodegener Dis; 2005; 2(5):267-72. PubMed ID: 16909008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of A beta plaque clearance following passive A beta immunization.
    Morgan D
    Neurodegener Dis; 2005; 2(5):261-6. PubMed ID: 16909007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-ß-directed immunotherapy for Alzheimer's disease.
    Lannfelt L; Relkin NR; Siemers ER
    J Intern Med; 2014 Mar; 275(3):284-95. PubMed ID: 24605809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
    Schenk DB; Seubert P; Grundman M; Black R
    Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Alzheimer's disease.
    Morgan D
    J Intern Med; 2011 Jan; 269(1):54-63. PubMed ID: 21158978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
    Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
    Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines for Alzheimer's disease: how close are we?
    Janus C
    CNS Drugs; 2003; 17(7):457-74. PubMed ID: 12751917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy for Alzheimer's disease targeting Aβ].
    Tabira T
    Nihon Rinsho; 2016 Mar; 74(3):423-6. PubMed ID: 27025080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide.
    Agadjanyan MG; Ghochikyan A; Petrushina I; Vasilevko V; Movsesyan N; Mkrtichyan M; Saing T; Cribbs DH
    J Immunol; 2005 Feb; 174(3):1580-6. PubMed ID: 15661919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology.
    Gnoth K; Piechotta A; Kleinschmidt M; Konrath S; Schenk M; Taudte N; Ramsbeck D; Rieckmann V; Geissler S; Eichentopf R; Barendrecht S; Hartlage-Rübsamen M; Demuth HU; Roßner S; Cynis H; Rahfeld JU; Schilling S
    Alzheimers Res Ther; 2020 Nov; 12(1):149. PubMed ID: 33189132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antibodies for immunotherapy of Alzheimer's disease].
    Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
    Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine development for Alzheimer's disease.
    Dasilva KA; Aubert I; McLaurin J
    Curr Pharm Des; 2006; 12(33):4283-93. PubMed ID: 17105428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies.
    Lathuilière A; Laversenne V; Astolfo A; Kopetzki E; Jacobsen H; Stampanoni M; Bohrmann B; Schneider BL; Aebischer P
    Brain; 2016 May; 139(Pt 5):1587-604. PubMed ID: 26956423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice.
    Lemere CA; Spooner ET; Leverone JF; Mori C; Iglesias M; Bloom JK; Seabrook TJ
    Neurochem Res; 2003 Jul; 28(7):1017-27. PubMed ID: 12737526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.